Molecular circuits of sex dimorphism in cardiometabolic traits and risk factors
Cardiometabolic traits and risk factors including cardiovascular diseases, type 2 diabetes, and hypertension are the leading causes of death worldwide. These conditions exhibit some degree of sex differences, including differences...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MOvE-ECG
Moving from genome wide association to elucidating causal me...
196K€
Cerrado
CGL2011-27866
VARIABILIDAD POBLACIONAL DE REGIONES GENOMICAS IDENTIFICADAS...
97K€
Cerrado
SEPI
Sequencing population isolates to find complex trait loci
1M€
Cerrado
CGL2014-53781-R
BIODIVERSIDAD GENETICA EN POBLACION DE CASTILLA Y LEON: APLI...
146K€
Cerrado
RTI2018-102084-B-I00
INFERENCIA DE REDES DE REGULACION GENICA A PARTIR DE DATOS D...
99K€
Cerrado
CARDIOPREVENT
INTEGRATION OF GENOMICS AND CARDIOMETABOLIC PLASMA BIOMARKER...
2M€
Cerrado
Información proyecto Sex Dimorphism
Duración del proyecto: 29 meses
Fecha Inicio: 2022-07-21
Fecha Fin: 2024-12-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Cardiometabolic traits and risk factors including cardiovascular diseases, type 2 diabetes, and hypertension are the leading causes of death worldwide. These conditions exhibit some degree of sex differences, including differences in incidence or prevalence, age of onset, severity, disease progression, susceptibility, response to treatment and pharmacological adverse events. Unfortunately, the reasons behind this sex dimorphism are largely unknown, hampering the realization of an effective personalized medicine.
My project will focus on understanding the genetic and molecular components that differentially impact men and women. I will first carry out sex stratified genome-wide association studies for cardiovascular diseases, type 2 diabetes, hypertension and obesity using large population biobanks to evaluate the effects of known-genetic variants within each sex and to identify novel loci that may have been previously undetected. I will then use molecular quantitative trait loci (QTLs) to identify specific gene expression changes and proteins modulated by these variants and that are likely to be involved in sex-specific development of cardiometabolic traits and modulation of risk factors. I will then validate putative causal genes using Mendelian randomization approaches.
This will lead to optimize therapeutics and find new drug target to perform equally well in males and females and will open the door to improve personalized and precision medicine in the near future.